Phase II clinical trial of Oxford Covid-19 vaccine begins in Pune

Two male volunteers were administered the vaccine at Bharti Vidyapeeth's Medical College and Hospital, a senior office-bearer of the hospital said

Phase II clinical trial of Oxford Covid-19 vaccine begins in Pune
Five volunteers had enrolled themselves for the trial after the doses were received from the SII on Tuesday
Press Trust of India Pune
2 min read Last Updated : Aug 27 2020 | 12:04 AM IST

The Phase II clinical trial of the Oxford Covid-19 vaccine, being manufactured by the city-based Serum Institute of India (SII), began at a medical college and hospital here on Wednesday.

Two male volunteers were administered the vaccine at Bharti Vidyapeeth's Medical College and Hospital, a senior office-bearer of the hospital said.

The trial began around 1 pm, he said.

"Doctors at the hospital administered the first shot of the 'Covishield' vaccine to a 32-year-old man after his reports of Covid-19 and antibodies tests came out negative," Medical Director of Bharti Vidyapeeth's Medical College, Hospital and Research Centre, Dr Sanjay Lalwani, said.

Another 48-year-old male volunteer was also given the vaccine, he added.

While the 32 year-old volunteer works for a private company, the other one is associated with the healthcare sector, he said.

"Before administering the vaccine, doctors checked their temperature, blood pressure and heart beats," he said.

Five volunteers had enrolled themselves for the trial after the doses were received from the SII on Tuesday, he added.

"The Covid-19 and antibodies tests were conducted on all the five volunteers. Of them, the reports of three volunteers' antibodies test came out positive. So they became ineligible for the trial," Dr Lalwani said.

"The two other volunteers, who were administered the vaccines are being monitored," he said.

According to Dr Lalwani, in all, 25 candidates will given the vaccine in the next seven days.

SII, the world's largest vaccine maker, has signed an agreement to manufacture the potential vaccine developed by the Jenner Institute of Oxford University in collaboration with British-Swedish pharma company AstraZeneca.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Coronavirus VaccineOxford UniversitySerum Institute of India

First Published: Aug 26 2020 | 6:06 PM IST

Next Story